SlideShare une entreprise Scribd logo
1  sur  54
Tutor Mikrobiologi TES KEPEKAAN ANTIMIKROBA Sri Kartika Sari / Jusak Nugraha Kamis, 11 Maret 2010 1
PENDAHULUAN Tujuan tes kepekaan antimikroba 2
Prinsip Umum Metode Dilusi Metode Difusi 3
Metode Dilusi Memungkinkan kuantitasi hasil : Jumlah antimikroba yang harus diberikan untuk menghambat atau membunuh bakteri yang dites. 4 Koneman’s Color Atlas and Textbook of Diagnostic Microbiology
Metode Difusi Metode disc diffusionThe Kirby-Bauer test Hasil kualitatif             berkorelasi dengan hasil kuantitatif dari tes MIC. 5
Persiapan inokulum Bakteri diambil dari Pure Culture Jumlah bakteri yang akan diinokulasi          standar 0,5 McFarland. 6
Pemilihan antimikroba Jenis obat yang rutin digunakan untuk tes kepekaan : 7
8 Basic Laboratory Procedure in Clinical Bacteriology (WHO,2006)
Broth Dilution methode  128   64    32    16     8     4     2   C1  C2  64    32    16      8      4     2    1   C1  C2  Hari 1 1 ml organisme (1x106 CFU/ml) ditambah 1ml  konsentrasi broth dan antimikroba (mg/L) C1 : tanpa antibiotik C2: tanpa organisme Konsentrasi organisme 5x105CFU/ml Inkubasi pada 35oC 9
64    32    16      8      4     2    1   C1  C2  64                32                16 Hari 2 Kultur tabung yang tidak keruh dengan ose 0,01ml MIC = 16 mg/L Hari 3 Menentukan CFU pada plate, pada 16 mg/L = 700 CFU /ml > 0,1% dari 5x105CFU/ml MBC= 32 mg/L 0,01 ml, inkubasi pada 35o C 10
Agar Dilution Methode Prosedur : 64 μg/ml 16 μg/ml 32 μg/ml 11 32μg/ml
12
Disc Diffusion Method(The Kirby-Bauer test) Ambil 3-5  koloni dari agar plate Masukkan ke dalam broth atau larutan salin 0,9% Basic Laboratory  Procedure in Clinical Bacteriology (WHO,2006) 13
Dengan menggunakan swab steril, ambil campuran bakteri dengan larutan broth/salin  Sesuaikan dengan standar 0,5 McFarland 14 Inokulasikan pada agar plate
Letakkan disc diatas agar, dengan menggunakan forcep atau dispenser Setelah inkubasi semalam pada 35˚ C, baca diameter zone inhibisi 15
Pembacaan hasil Catatan : Pada tes oxacillin dengan Staphylococci dan vancomycin dengan Enterococci         bila dilihat dengan penyinaran/alat pembesar, koloni kecil diabaikan. Swarming Proteus spp diabaikan Adanya pertumbuhan tipis pada zone sulfonamide, trimetoprim-sulfametokzasol diabaikan,          ukur tepi pertumbuhan tebal. Adanya pertumbuhan koloni yang besar dalam zone inhibisi menunjukkan mixed culture        ulang 16
17 Basic Laboratory  Procedure in Clinical Bacteriology (WHO,2006)
Faktor yang mempengaruhi zone inhibisi : Media pertumbuhan pH Temperatur Cation consentration Atmosphere Inokulum Antibiotic disc 18
Etest Etest        strip berisi gradien konsentrasi antimikroba Prinsip : Standar inokulum bakteri diinokulasikan pada Muller Hinton Agar. Strip Etest diletakkan diatas permukaan agar, setelah inkubasi akan terbentuk zone inhibisi. MIC dibaca pada pertumbuhan yang menyilang strip Etest. 19
Prosedur : 20
21
Penutup Tes kepekaan antimikroba merupakan hal yang sangat penting untuk terapi dan menurunkan prevalensi resistensi kuman. 22
TERIMAKASIH 23
24
25
Inoculum The density of the suspension is adjusted to approximately 108 CFU/ml by comparing its turbidity to a McFarland 0,5 BaSO4 standard. The standard prepared by : 0,5 ml  0,048 M BaCl2 99,5 ml 0,36 N H2SO4 26
http: //en.wikipedia.org./wiki/file: antiboitic _action.png 27
28
29
30
31
Two new chromogenic media in the Oxoid Brilliance™ Resistant Screening Agar range are now available. Brilliance ESBL Agar and Brilliance VRE Agar can be used as screening tests to rapidly identify patients colonised with problematic Extended Spectrum Beta-Lactamase (ESBL) producing organisms and vancomycin resistant enterococci (VRE), allowing appropriate infection control and treatment to commence sooner for the best possible patient outcome. E. coli (blue colonies) and the KESC group (green colonies) on ESBL Agar 32
Brilliance VRE Agar is a chromogenic screening plate for the detection of VRE. Following direct inoculation from faecal sample, swab, isolate or suspension, the medium provides presumptive identification of Enterococcusfaecium and Enterococcusfaecaliswithin 24 hours. Differentiation of vancomycin resistant E. faecium from E. faecalis is achieved through the inclusion of two chromogens that are targeted by specific enzymes. The action of these enzymes on the chromogens results in a build-up of colour within the colony. The colour produced depends on which enzymes the organisms possess. Additional antibiotics are present in combination with vancomycin, to suppress the growth of competing flora including E. gallinarum and E. casseliflavus, both of which are intrinsically resistant to vancomycin. Rapidmicrobiology.com 33
KPCs are class A carbapenemases that reside on transferable plasmids and are capable of inactivating carbapenems, such as imipenem and meropenem. Since carbapenems are often used to treat infections caused by extended-spectrum beta lactamase (ESBL)-producing Gram-negative bacteria, carbapenemase production in Enterobacteriaceae can significantly limit treatment options for life-threatening diseases. KPCs occur most commonly in Klebsiellapneumoniae but have been seen in other species of Enterobacteraciae as well.CLSI (Clinical Laboratory Standards Institute) recommends the MHT be performed before reporting carbapenem susceptibility results if a clinical isolate has an elevated but susceptible carbapenem MIC. Susceptibility results may be reported without performing the MHT if a clinical isolate is intermediate or resistant to carbapenems, but clinical laboratories may want to perform the MHT for infection control and epidemiological reasons. 34
35
36
37
38
39
40
41
In the Stokes controlled sensitivity test, a control organism is inoculated on part of a plate and the test organism is plated on the remainder. Disks are placed at the interface and the zones of inhibition are compared. The use of a sensitive control shows that the antibiotic is active, so that if the test organism grows up to the disk it may safely be assumed that the test organism is resistant to that drug.   Stokes' sensitivity test The test bacterium in the diagram is susceptible to drug "x" but resistant to drug "y". The disk containing drug "y" contains active antibiotic as shown by the zone of inhibition it causes in the control bacterium http://.www.bmb.leed.ac.uk/mbiol...sts.html 42
  The VITEK® 2 compact is an automated bacterial identification and antibiotic susceptibility testing (ID/AST) system. Designed for small to midsize microbiology laboratories, the VITEK 2 compact offers an extensive ID and AST database to improve laboratory efficiency.      Using multi-spectrum colorimetric and transmittance optic systems, the VITEK 2 compact detects changes in organism growth under various media and antibiotic concentrations. The instrument’s advanced expert system interprets the antibiotic-resistance patterns, validates the results, and reports the resistance phenotype useful to patient treatment and infection control. The system offers rapid results, providing increased productivity and improved workflow.  bioMerieux 43
Antimicrobial Susceptibility Test (Broth Dilution)  This test used to test all the ABC isolates. This picture shows the most accurate method of determining the antimicrobial susceptibility of GBS. This test is called the broth dilution antimicrobial susceptibility test. It is standardized by the the National Committee on Clinical Laboratory Standards (NCCLS). The picture above shows a microtiter plate with 96 wells. There are 8 rows of wells, labeled A through G. Each row of wells contains one antibiotic. In each row there are 12 wells. Each well contains a different concentration of the specific antibiotic, usually doubling dilutions. In this case, row A contains penicillin starting at the right at 16 ?g/ml and reducing to 0.008 well 12. Row B contains ampicillin starting in well 1 with 16 ?g/ml and reducing to 0.008 ?g/ml to well 12 in the same row. The other rows contain different antibiotics. All 96 wells are inoculated at the same time and the panel is incubated overnight (20-24h). The next day the wells are examined for growth. If there is growth in the well, the antibiotic did not inhibit the bacteria. If you take a close look in row A you will see growth (a small white button at the bottom of the well) only in well 12. In row B you see growth in both well 11 and 12. This means the minimum inhibitory concentration (MIC) of penicillin is 0.016 ?g/ml and the MIC for ampicillin is 0.032 ?g/ml. The MIC’s of these antimicrobials are considered susceptible for,GBS. Erythromycin is shown is row F. The concentration of erythromycin starts at 32 ?g/ml in well 1 and goes to 0.016 ?g/ml in well 12. You can see that there is growth in wells 12 to 4, meaning the MIC of erythromycin to this strain is 8 ?g/ml. This MIC is considered resistant for GBS. Since this is a standardized test results can be compared world-wide if the standard procedures are used. Consult the NCCLS manual for reporting interpretive standards (sensitive, intermediate, and resistance).NCCLS Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement: M100-12 (2002) M2-A7 and M7-A5.  44
Testing of streptococcal isolates with erythromycin and clindamycin disks applied close together can often yield phenotypic information, although it is not always possible to differentiate between phenotypes using this method. See J. Clin. Microbiol 2001;39:1311-1315 for details of this method for phenotypic analysis of S. pneumoniae. The figures below are taken from that paper, with some major modifications made to simplify this discussion; see the paper for the real and more complicated story.                           45
Densitometer ,[object Object],A compact and efficient benchtop densitometer, the DEN-1 is designed to measure turbidity in the range of 0.3 to 5.0 McFarland units with a small standard deviation. If required, it can deliver a wider measurement range (up to 15.0 McFarland units) but with a greater standard deviation.  Typical applications of the DEN-1 Densitometer includes:  Determining concentration of cells (bactorial and yeast) in the fermentation process  Detecting the susceptibility of micro-organisms to antibiotics  Identifying micro-organisms with various test systems  Measuring optical density at fixed wavelength 46
47
48
49
50
51
52
53
54

Contenu connexe

Tendances

Tendances (20)

Trichuriasis
TrichuriasisTrichuriasis
Trichuriasis
 
Klt ku
Klt kuKlt ku
Klt ku
 
Isolasi dan morfologi koloni bakteri
Isolasi  dan  morfologi koloni bakteriIsolasi  dan  morfologi koloni bakteri
Isolasi dan morfologi koloni bakteri
 
Tugas elisa gandi
Tugas elisa gandiTugas elisa gandi
Tugas elisa gandi
 
Spektrofotometer UV
Spektrofotometer UVSpektrofotometer UV
Spektrofotometer UV
 
Sistem komplemen
Sistem komplemenSistem komplemen
Sistem komplemen
 
Penanaman bakteri pada nutrien agar miring
Penanaman bakteri pada nutrien agar miringPenanaman bakteri pada nutrien agar miring
Penanaman bakteri pada nutrien agar miring
 
High Performance Liquid Chromatography
High Performance Liquid ChromatographyHigh Performance Liquid Chromatography
High Performance Liquid Chromatography
 
Uji potensi antibiotik secara mikrobiologi
Uji potensi antibiotik secara mikrobiologiUji potensi antibiotik secara mikrobiologi
Uji potensi antibiotik secara mikrobiologi
 
Uji Disolusi
Uji DisolusiUji Disolusi
Uji Disolusi
 
Penicillium Paecilomyces Aspergillus
Penicillium Paecilomyces AspergillusPenicillium Paecilomyces Aspergillus
Penicillium Paecilomyces Aspergillus
 
Chapter iii vi
Chapter iii viChapter iii vi
Chapter iii vi
 
Evaluasi Granul
Evaluasi GranulEvaluasi Granul
Evaluasi Granul
 
Farmakokinetik dan farmakodinamik
Farmakokinetik dan farmakodinamikFarmakokinetik dan farmakodinamik
Farmakokinetik dan farmakodinamik
 
Gc ms
Gc msGc ms
Gc ms
 
Self assesment iso 15189
Self assesment iso 15189Self assesment iso 15189
Self assesment iso 15189
 
Obat antidiare
Obat antidiareObat antidiare
Obat antidiare
 
Metabolit sekunder hewan laut.
Metabolit sekunder hewan laut.Metabolit sekunder hewan laut.
Metabolit sekunder hewan laut.
 
Karakteristik kromatografi
Karakteristik kromatografiKarakteristik kromatografi
Karakteristik kromatografi
 
CARIK CELUP URINE (REFLACTAN)
CARIK CELUP URINE (REFLACTAN)CARIK CELUP URINE (REFLACTAN)
CARIK CELUP URINE (REFLACTAN)
 

En vedette

Introduction to sulphonamides, trimethoprim, quinolones, penicillins, cephalo...
Introduction to sulphonamides, trimethoprim, quinolones, penicillins, cephalo...Introduction to sulphonamides, trimethoprim, quinolones, penicillins, cephalo...
Introduction to sulphonamides, trimethoprim, quinolones, penicillins, cephalo...Subramani Parasuraman
 
Folic Acid Synthesis Inhibitors
Folic Acid Synthesis InhibitorsFolic Acid Synthesis Inhibitors
Folic Acid Synthesis InhibitorsDr Shah Murad
 
Aminoglycosides(medicinal chemistry by p.ravisankar)
Aminoglycosides(medicinal chemistry by p.ravisankar)Aminoglycosides(medicinal chemistry by p.ravisankar)
Aminoglycosides(medicinal chemistry by p.ravisankar)Dr. Ravi Sankar
 
Antimicrobial
AntimicrobialAntimicrobial
Antimicrobialgirlie
 
Aminoglycoside ppt
Aminoglycoside pptAminoglycoside ppt
Aminoglycoside pptneetu ojha
 
3. ANTIBIOTIC (PROTEIN SYNTHESIS INHIBITORS)
3. ANTIBIOTIC (PROTEIN SYNTHESIS INHIBITORS)3. ANTIBIOTIC (PROTEIN SYNTHESIS INHIBITORS)
3. ANTIBIOTIC (PROTEIN SYNTHESIS INHIBITORS)Saminathan Kayarohanam
 
Ch 20_lecture_presentation
 Ch 20_lecture_presentation Ch 20_lecture_presentation
Ch 20_lecture_presentationkevperrino
 
DIARIO DE CIENCIAS PSÍQUICAS Nº1 - marzo 2017
DIARIO DE CIENCIAS PSÍQUICAS  Nº1 - marzo 2017DIARIO DE CIENCIAS PSÍQUICAS  Nº1 - marzo 2017
DIARIO DE CIENCIAS PSÍQUICAS Nº1 - marzo 2017cienciaspsiquicas
 
Protein synthesis inhibitor antibiotics
Protein synthesis inhibitor antibioticsProtein synthesis inhibitor antibiotics
Protein synthesis inhibitor antibioticsRukiga District
 
Antimicrobial 3 protein synthesis inhibitors
Antimicrobial 3 protein synthesis inhibitorsAntimicrobial 3 protein synthesis inhibitors
Antimicrobial 3 protein synthesis inhibitorsAseenat Mansour
 
Tuberculosis and anti tubercular drugs
Tuberculosis and anti tubercular drugsTuberculosis and anti tubercular drugs
Tuberculosis and anti tubercular drugsNarasimha Kumar G V
 
Sulfonamides and trimethoprim
Sulfonamides and trimethoprimSulfonamides and trimethoprim
Sulfonamides and trimethoprimAbhinav Sawhney
 
ما هي كلوستريديم ديفيسيل ؟
ما هي كلوستريديم  ديفيسيل ؟ما هي كلوستريديم  ديفيسيل ؟
ما هي كلوستريديم ديفيسيل ؟Univ. of Tripoli
 
ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.
ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.
ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.Dr. Ravi Sankar
 

En vedette (20)

2.sulfonamides
2.sulfonamides2.sulfonamides
2.sulfonamides
 
Introduction to sulphonamides, trimethoprim, quinolones, penicillins, cephalo...
Introduction to sulphonamides, trimethoprim, quinolones, penicillins, cephalo...Introduction to sulphonamides, trimethoprim, quinolones, penicillins, cephalo...
Introduction to sulphonamides, trimethoprim, quinolones, penicillins, cephalo...
 
Folic Acid Synthesis Inhibitors
Folic Acid Synthesis InhibitorsFolic Acid Synthesis Inhibitors
Folic Acid Synthesis Inhibitors
 
Obat antimikroba
Obat antimikrobaObat antimikroba
Obat antimikroba
 
sulfoamide
sulfoamidesulfoamide
sulfoamide
 
Antibiotics
AntibioticsAntibiotics
Antibiotics
 
Aminoglycosides(medicinal chemistry by p.ravisankar)
Aminoglycosides(medicinal chemistry by p.ravisankar)Aminoglycosides(medicinal chemistry by p.ravisankar)
Aminoglycosides(medicinal chemistry by p.ravisankar)
 
Antimicrobial
AntimicrobialAntimicrobial
Antimicrobial
 
Aminoglycoside ppt
Aminoglycoside pptAminoglycoside ppt
Aminoglycoside ppt
 
3. ANTIBIOTIC (PROTEIN SYNTHESIS INHIBITORS)
3. ANTIBIOTIC (PROTEIN SYNTHESIS INHIBITORS)3. ANTIBIOTIC (PROTEIN SYNTHESIS INHIBITORS)
3. ANTIBIOTIC (PROTEIN SYNTHESIS INHIBITORS)
 
Ch 20_lecture_presentation
 Ch 20_lecture_presentation Ch 20_lecture_presentation
Ch 20_lecture_presentation
 
DIARIO DE CIENCIAS PSÍQUICAS Nº1 - marzo 2017
DIARIO DE CIENCIAS PSÍQUICAS  Nº1 - marzo 2017DIARIO DE CIENCIAS PSÍQUICAS  Nº1 - marzo 2017
DIARIO DE CIENCIAS PSÍQUICAS Nº1 - marzo 2017
 
Protein synthesis inhibitor antibiotics
Protein synthesis inhibitor antibioticsProtein synthesis inhibitor antibiotics
Protein synthesis inhibitor antibiotics
 
Antimicrobial 3 protein synthesis inhibitors
Antimicrobial 3 protein synthesis inhibitorsAntimicrobial 3 protein synthesis inhibitors
Antimicrobial 3 protein synthesis inhibitors
 
Tuberculosis and anti tubercular drugs
Tuberculosis and anti tubercular drugsTuberculosis and anti tubercular drugs
Tuberculosis and anti tubercular drugs
 
Sulfonamides and trimethoprim
Sulfonamides and trimethoprimSulfonamides and trimethoprim
Sulfonamides and trimethoprim
 
Antimicrobials
AntimicrobialsAntimicrobials
Antimicrobials
 
ما هي كلوستريديم ديفيسيل ؟
ما هي كلوستريديم  ديفيسيل ؟ما هي كلوستريديم  ديفيسيل ؟
ما هي كلوستريديم ديفيسيل ؟
 
ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.
ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.
ANTI-TB AND ANTI LEPROTIC DRUGS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.
 
Sulfonamides and trimethoprim
Sulfonamides and trimethoprimSulfonamides and trimethoprim
Sulfonamides and trimethoprim
 

Similaire à Tpibaru8

ESBL and mbl-method of detection-1.pptx
ESBL and mbl-method of detection-1.pptxESBL and mbl-method of detection-1.pptx
ESBL and mbl-method of detection-1.pptxAnanya147165
 
Antimicrobial susceptibility test and assay bls 209
Antimicrobial susceptibility test and assay bls 209Antimicrobial susceptibility test and assay bls 209
Antimicrobial susceptibility test and assay bls 209Bruno Mmassy
 
Antibiotic sensitivity testing
Antibiotic sensitivity testingAntibiotic sensitivity testing
Antibiotic sensitivity testingPrbn Shah
 
Microbiological culture sensitivity test
Microbiological culture sensitivity testMicrobiological culture sensitivity test
Microbiological culture sensitivity testSuhas Reddy C
 
6-laboratorydiagnosisofbacterialinfection-150727150744-lva1-app6892.pdf
6-laboratorydiagnosisofbacterialinfection-150727150744-lva1-app6892.pdf6-laboratorydiagnosisofbacterialinfection-150727150744-lva1-app6892.pdf
6-laboratorydiagnosisofbacterialinfection-150727150744-lva1-app6892.pdfStephenNjoroge22
 
6-laboratorydiagnosisofbacterialinfection.pdf
6-laboratorydiagnosisofbacterialinfection.pdf6-laboratorydiagnosisofbacterialinfection.pdf
6-laboratorydiagnosisofbacterialinfection.pdfsknjoroge
 
6 laboratory diagnosis of bacterial infection
6 laboratory diagnosis  of bacterial infection6 laboratory diagnosis  of bacterial infection
6 laboratory diagnosis of bacterial infectionPrabesh Raj Jamkatel
 
AST Methods_Practical No. 8.pptx
AST Methods_Practical No. 8.pptxAST Methods_Practical No. 8.pptx
AST Methods_Practical No. 8.pptxJohnreeEvangelista1
 
Antimicrobial sensitivity testing
Antimicrobial sensitivity testing  Antimicrobial sensitivity testing
Antimicrobial sensitivity testing Dr.Dinesh Jain
 
Medical Microbiology Laboratory (Antibiotics Sensitivity Testing)
Medical Microbiology Laboratory (Antibiotics Sensitivity Testing)Medical Microbiology Laboratory (Antibiotics Sensitivity Testing)
Medical Microbiology Laboratory (Antibiotics Sensitivity Testing)Hussein Al-tameemi
 
Antimicrobial assay.pptx
Antimicrobial assay.pptxAntimicrobial assay.pptx
Antimicrobial assay.pptxRudiHendra
 
1 KEFLEX® CAPSULES CEPHALEXIN, USP To reduce.docx
1 KEFLEX® CAPSULES CEPHALEXIN, USP  To reduce.docx1 KEFLEX® CAPSULES CEPHALEXIN, USP  To reduce.docx
1 KEFLEX® CAPSULES CEPHALEXIN, USP To reduce.docxadkinspaige22
 
Microbiological Culture sensitivity tests
Microbiological Culture sensitivity testsMicrobiological Culture sensitivity tests
Microbiological Culture sensitivity testsDr Vimali
 
Abdominal Tuberculosis – How Far are Our Diagnostics Illuminating?
Abdominal Tuberculosis – How Far are Our Diagnostics Illuminating?Abdominal Tuberculosis – How Far are Our Diagnostics Illuminating?
Abdominal Tuberculosis – How Far are Our Diagnostics Illuminating?Apollo Hospitals
 
Multi drug resistant organisims
Multi drug resistant organisimsMulti drug resistant organisims
Multi drug resistant organisimsJayant Balani
 
antimicrobial chemotherapy
antimicrobial chemotherapyantimicrobial chemotherapy
antimicrobial chemotherapyAshish Jawarkar
 
Microbiological culture sensitivity test
Microbiological culture sensitivity testMicrobiological culture sensitivity test
Microbiological culture sensitivity testAkhil Joseph
 
Testing 68
Testing 68Testing 68
Testing 68guru99
 

Similaire à Tpibaru8 (20)

ESBL and mbl-method of detection-1.pptx
ESBL and mbl-method of detection-1.pptxESBL and mbl-method of detection-1.pptx
ESBL and mbl-method of detection-1.pptx
 
Antimicrobial susceptibility test and assay bls 209
Antimicrobial susceptibility test and assay bls 209Antimicrobial susceptibility test and assay bls 209
Antimicrobial susceptibility test and assay bls 209
 
Antimicrobial test
Antimicrobial testAntimicrobial test
Antimicrobial test
 
Antibiotic sensitivity testing
Antibiotic sensitivity testingAntibiotic sensitivity testing
Antibiotic sensitivity testing
 
Microbiological culture sensitivity test
Microbiological culture sensitivity testMicrobiological culture sensitivity test
Microbiological culture sensitivity test
 
6-laboratorydiagnosisofbacterialinfection-150727150744-lva1-app6892.pdf
6-laboratorydiagnosisofbacterialinfection-150727150744-lva1-app6892.pdf6-laboratorydiagnosisofbacterialinfection-150727150744-lva1-app6892.pdf
6-laboratorydiagnosisofbacterialinfection-150727150744-lva1-app6892.pdf
 
6-laboratorydiagnosisofbacterialinfection.pdf
6-laboratorydiagnosisofbacterialinfection.pdf6-laboratorydiagnosisofbacterialinfection.pdf
6-laboratorydiagnosisofbacterialinfection.pdf
 
6 laboratory diagnosis of bacterial infection
6 laboratory diagnosis  of bacterial infection6 laboratory diagnosis  of bacterial infection
6 laboratory diagnosis of bacterial infection
 
AST Methods_Practical No. 8.pptx
AST Methods_Practical No. 8.pptxAST Methods_Practical No. 8.pptx
AST Methods_Practical No. 8.pptx
 
Antimicrobial sensitivity testing
Antimicrobial sensitivity testing  Antimicrobial sensitivity testing
Antimicrobial sensitivity testing
 
Detection of Biofilm
Detection of BiofilmDetection of Biofilm
Detection of Biofilm
 
Medical Microbiology Laboratory (Antibiotics Sensitivity Testing)
Medical Microbiology Laboratory (Antibiotics Sensitivity Testing)Medical Microbiology Laboratory (Antibiotics Sensitivity Testing)
Medical Microbiology Laboratory (Antibiotics Sensitivity Testing)
 
Antimicrobial assay.pptx
Antimicrobial assay.pptxAntimicrobial assay.pptx
Antimicrobial assay.pptx
 
1 KEFLEX® CAPSULES CEPHALEXIN, USP To reduce.docx
1 KEFLEX® CAPSULES CEPHALEXIN, USP  To reduce.docx1 KEFLEX® CAPSULES CEPHALEXIN, USP  To reduce.docx
1 KEFLEX® CAPSULES CEPHALEXIN, USP To reduce.docx
 
Microbiological Culture sensitivity tests
Microbiological Culture sensitivity testsMicrobiological Culture sensitivity tests
Microbiological Culture sensitivity tests
 
Abdominal Tuberculosis – How Far are Our Diagnostics Illuminating?
Abdominal Tuberculosis – How Far are Our Diagnostics Illuminating?Abdominal Tuberculosis – How Far are Our Diagnostics Illuminating?
Abdominal Tuberculosis – How Far are Our Diagnostics Illuminating?
 
Multi drug resistant organisims
Multi drug resistant organisimsMulti drug resistant organisims
Multi drug resistant organisims
 
antimicrobial chemotherapy
antimicrobial chemotherapyantimicrobial chemotherapy
antimicrobial chemotherapy
 
Microbiological culture sensitivity test
Microbiological culture sensitivity testMicrobiological culture sensitivity test
Microbiological culture sensitivity test
 
Testing 68
Testing 68Testing 68
Testing 68
 

Plus de andreei

Plus de andreei (20)

Tibaru18
Tibaru18Tibaru18
Tibaru18
 
Tibaru17
Tibaru17Tibaru17
Tibaru17
 
Tibaru16
Tibaru16Tibaru16
Tibaru16
 
Tibaru15
Tibaru15Tibaru15
Tibaru15
 
Tibaru14
Tibaru14Tibaru14
Tibaru14
 
Tibaru13
Tibaru13Tibaru13
Tibaru13
 
Tibaru12
Tibaru12Tibaru12
Tibaru12
 
Tibaru11
Tibaru11Tibaru11
Tibaru11
 
Tibaru9
Tibaru9Tibaru9
Tibaru9
 
Tibaru11
Tibaru11Tibaru11
Tibaru11
 
Tibaru10
Tibaru10Tibaru10
Tibaru10
 
Tibaru8
Tibaru8Tibaru8
Tibaru8
 
Tibaru7
Tibaru7Tibaru7
Tibaru7
 
Refhemabaru8
Refhemabaru8Refhemabaru8
Refhemabaru8
 
Refhemabaru7
Refhemabaru7Refhemabaru7
Refhemabaru7
 
Refhemabaru6
Refhemabaru6Refhemabaru6
Refhemabaru6
 
Refhemabaru5
Refhemabaru5Refhemabaru5
Refhemabaru5
 
12
1212
12
 
12
1212
12
 
11
1111
11
 

Dernier

Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24Mark Goldstein
 
TrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data PrivacyTrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data PrivacyTrustArc
 
(How to Program) Paul Deitel, Harvey Deitel-Java How to Program, Early Object...
(How to Program) Paul Deitel, Harvey Deitel-Java How to Program, Early Object...(How to Program) Paul Deitel, Harvey Deitel-Java How to Program, Early Object...
(How to Program) Paul Deitel, Harvey Deitel-Java How to Program, Early Object...AliaaTarek5
 
[Webinar] SpiraTest - Setting New Standards in Quality Assurance
[Webinar] SpiraTest - Setting New Standards in Quality Assurance[Webinar] SpiraTest - Setting New Standards in Quality Assurance
[Webinar] SpiraTest - Setting New Standards in Quality AssuranceInflectra
 
Manual 508 Accessibility Compliance Audit
Manual 508 Accessibility Compliance AuditManual 508 Accessibility Compliance Audit
Manual 508 Accessibility Compliance AuditSkynet Technologies
 
From Family Reminiscence to Scholarly Archive .
From Family Reminiscence to Scholarly Archive .From Family Reminiscence to Scholarly Archive .
From Family Reminiscence to Scholarly Archive .Alan Dix
 
The State of Passkeys with FIDO Alliance.pptx
The State of Passkeys with FIDO Alliance.pptxThe State of Passkeys with FIDO Alliance.pptx
The State of Passkeys with FIDO Alliance.pptxLoriGlavin3
 
Use of FIDO in the Payments and Identity Landscape: FIDO Paris Seminar.pptx
Use of FIDO in the Payments and Identity Landscape: FIDO Paris Seminar.pptxUse of FIDO in the Payments and Identity Landscape: FIDO Paris Seminar.pptx
Use of FIDO in the Payments and Identity Landscape: FIDO Paris Seminar.pptxLoriGlavin3
 
Potential of AI (Generative AI) in Business: Learnings and Insights
Potential of AI (Generative AI) in Business: Learnings and InsightsPotential of AI (Generative AI) in Business: Learnings and Insights
Potential of AI (Generative AI) in Business: Learnings and InsightsRavi Sanghani
 
UiPath Community: Communication Mining from Zero to Hero
UiPath Community: Communication Mining from Zero to HeroUiPath Community: Communication Mining from Zero to Hero
UiPath Community: Communication Mining from Zero to HeroUiPathCommunity
 
Testing tools and AI - ideas what to try with some tool examples
Testing tools and AI - ideas what to try with some tool examplesTesting tools and AI - ideas what to try with some tool examples
Testing tools and AI - ideas what to try with some tool examplesKari Kakkonen
 
Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...
Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...
Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...Scott Andery
 
Moving Beyond Passwords: FIDO Paris Seminar.pdf
Moving Beyond Passwords: FIDO Paris Seminar.pdfMoving Beyond Passwords: FIDO Paris Seminar.pdf
Moving Beyond Passwords: FIDO Paris Seminar.pdfLoriGlavin3
 
A Framework for Development in the AI Age
A Framework for Development in the AI AgeA Framework for Development in the AI Age
A Framework for Development in the AI AgeCprime
 
Take control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteTake control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteDianaGray10
 
Time Series Foundation Models - current state and future directions
Time Series Foundation Models - current state and future directionsTime Series Foundation Models - current state and future directions
Time Series Foundation Models - current state and future directionsNathaniel Shimoni
 
Scale your database traffic with Read & Write split using MySQL Router
Scale your database traffic with Read & Write split using MySQL RouterScale your database traffic with Read & Write split using MySQL Router
Scale your database traffic with Read & Write split using MySQL RouterMydbops
 
TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024Lonnie McRorey
 
Decarbonising Buildings: Making a net-zero built environment a reality
Decarbonising Buildings: Making a net-zero built environment a realityDecarbonising Buildings: Making a net-zero built environment a reality
Decarbonising Buildings: Making a net-zero built environment a realityIES VE
 
DevEX - reference for building teams, processes, and platforms
DevEX - reference for building teams, processes, and platformsDevEX - reference for building teams, processes, and platforms
DevEX - reference for building teams, processes, and platformsSergiu Bodiu
 

Dernier (20)

Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
Arizona Broadband Policy Past, Present, and Future Presentation 3/25/24
 
TrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data PrivacyTrustArc Webinar - How to Build Consumer Trust Through Data Privacy
TrustArc Webinar - How to Build Consumer Trust Through Data Privacy
 
(How to Program) Paul Deitel, Harvey Deitel-Java How to Program, Early Object...
(How to Program) Paul Deitel, Harvey Deitel-Java How to Program, Early Object...(How to Program) Paul Deitel, Harvey Deitel-Java How to Program, Early Object...
(How to Program) Paul Deitel, Harvey Deitel-Java How to Program, Early Object...
 
[Webinar] SpiraTest - Setting New Standards in Quality Assurance
[Webinar] SpiraTest - Setting New Standards in Quality Assurance[Webinar] SpiraTest - Setting New Standards in Quality Assurance
[Webinar] SpiraTest - Setting New Standards in Quality Assurance
 
Manual 508 Accessibility Compliance Audit
Manual 508 Accessibility Compliance AuditManual 508 Accessibility Compliance Audit
Manual 508 Accessibility Compliance Audit
 
From Family Reminiscence to Scholarly Archive .
From Family Reminiscence to Scholarly Archive .From Family Reminiscence to Scholarly Archive .
From Family Reminiscence to Scholarly Archive .
 
The State of Passkeys with FIDO Alliance.pptx
The State of Passkeys with FIDO Alliance.pptxThe State of Passkeys with FIDO Alliance.pptx
The State of Passkeys with FIDO Alliance.pptx
 
Use of FIDO in the Payments and Identity Landscape: FIDO Paris Seminar.pptx
Use of FIDO in the Payments and Identity Landscape: FIDO Paris Seminar.pptxUse of FIDO in the Payments and Identity Landscape: FIDO Paris Seminar.pptx
Use of FIDO in the Payments and Identity Landscape: FIDO Paris Seminar.pptx
 
Potential of AI (Generative AI) in Business: Learnings and Insights
Potential of AI (Generative AI) in Business: Learnings and InsightsPotential of AI (Generative AI) in Business: Learnings and Insights
Potential of AI (Generative AI) in Business: Learnings and Insights
 
UiPath Community: Communication Mining from Zero to Hero
UiPath Community: Communication Mining from Zero to HeroUiPath Community: Communication Mining from Zero to Hero
UiPath Community: Communication Mining from Zero to Hero
 
Testing tools and AI - ideas what to try with some tool examples
Testing tools and AI - ideas what to try with some tool examplesTesting tools and AI - ideas what to try with some tool examples
Testing tools and AI - ideas what to try with some tool examples
 
Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...
Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...
Enhancing User Experience - Exploring the Latest Features of Tallyman Axis Lo...
 
Moving Beyond Passwords: FIDO Paris Seminar.pdf
Moving Beyond Passwords: FIDO Paris Seminar.pdfMoving Beyond Passwords: FIDO Paris Seminar.pdf
Moving Beyond Passwords: FIDO Paris Seminar.pdf
 
A Framework for Development in the AI Age
A Framework for Development in the AI AgeA Framework for Development in the AI Age
A Framework for Development in the AI Age
 
Take control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test SuiteTake control of your SAP testing with UiPath Test Suite
Take control of your SAP testing with UiPath Test Suite
 
Time Series Foundation Models - current state and future directions
Time Series Foundation Models - current state and future directionsTime Series Foundation Models - current state and future directions
Time Series Foundation Models - current state and future directions
 
Scale your database traffic with Read & Write split using MySQL Router
Scale your database traffic with Read & Write split using MySQL RouterScale your database traffic with Read & Write split using MySQL Router
Scale your database traffic with Read & Write split using MySQL Router
 
TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024TeamStation AI System Report LATAM IT Salaries 2024
TeamStation AI System Report LATAM IT Salaries 2024
 
Decarbonising Buildings: Making a net-zero built environment a reality
Decarbonising Buildings: Making a net-zero built environment a realityDecarbonising Buildings: Making a net-zero built environment a reality
Decarbonising Buildings: Making a net-zero built environment a reality
 
DevEX - reference for building teams, processes, and platforms
DevEX - reference for building teams, processes, and platformsDevEX - reference for building teams, processes, and platforms
DevEX - reference for building teams, processes, and platforms
 

Tpibaru8

  • 1. Tutor Mikrobiologi TES KEPEKAAN ANTIMIKROBA Sri Kartika Sari / Jusak Nugraha Kamis, 11 Maret 2010 1
  • 2. PENDAHULUAN Tujuan tes kepekaan antimikroba 2
  • 3. Prinsip Umum Metode Dilusi Metode Difusi 3
  • 4. Metode Dilusi Memungkinkan kuantitasi hasil : Jumlah antimikroba yang harus diberikan untuk menghambat atau membunuh bakteri yang dites. 4 Koneman’s Color Atlas and Textbook of Diagnostic Microbiology
  • 5. Metode Difusi Metode disc diffusionThe Kirby-Bauer test Hasil kualitatif berkorelasi dengan hasil kuantitatif dari tes MIC. 5
  • 6. Persiapan inokulum Bakteri diambil dari Pure Culture Jumlah bakteri yang akan diinokulasi standar 0,5 McFarland. 6
  • 7. Pemilihan antimikroba Jenis obat yang rutin digunakan untuk tes kepekaan : 7
  • 8. 8 Basic Laboratory Procedure in Clinical Bacteriology (WHO,2006)
  • 9. Broth Dilution methode 128 64 32 16 8 4 2 C1 C2 64 32 16 8 4 2 1 C1 C2 Hari 1 1 ml organisme (1x106 CFU/ml) ditambah 1ml konsentrasi broth dan antimikroba (mg/L) C1 : tanpa antibiotik C2: tanpa organisme Konsentrasi organisme 5x105CFU/ml Inkubasi pada 35oC 9
  • 10. 64 32 16 8 4 2 1 C1 C2 64 32 16 Hari 2 Kultur tabung yang tidak keruh dengan ose 0,01ml MIC = 16 mg/L Hari 3 Menentukan CFU pada plate, pada 16 mg/L = 700 CFU /ml > 0,1% dari 5x105CFU/ml MBC= 32 mg/L 0,01 ml, inkubasi pada 35o C 10
  • 11. Agar Dilution Methode Prosedur : 64 μg/ml 16 μg/ml 32 μg/ml 11 32μg/ml
  • 12. 12
  • 13. Disc Diffusion Method(The Kirby-Bauer test) Ambil 3-5 koloni dari agar plate Masukkan ke dalam broth atau larutan salin 0,9% Basic Laboratory Procedure in Clinical Bacteriology (WHO,2006) 13
  • 14. Dengan menggunakan swab steril, ambil campuran bakteri dengan larutan broth/salin Sesuaikan dengan standar 0,5 McFarland 14 Inokulasikan pada agar plate
  • 15. Letakkan disc diatas agar, dengan menggunakan forcep atau dispenser Setelah inkubasi semalam pada 35˚ C, baca diameter zone inhibisi 15
  • 16. Pembacaan hasil Catatan : Pada tes oxacillin dengan Staphylococci dan vancomycin dengan Enterococci bila dilihat dengan penyinaran/alat pembesar, koloni kecil diabaikan. Swarming Proteus spp diabaikan Adanya pertumbuhan tipis pada zone sulfonamide, trimetoprim-sulfametokzasol diabaikan, ukur tepi pertumbuhan tebal. Adanya pertumbuhan koloni yang besar dalam zone inhibisi menunjukkan mixed culture ulang 16
  • 17. 17 Basic Laboratory Procedure in Clinical Bacteriology (WHO,2006)
  • 18. Faktor yang mempengaruhi zone inhibisi : Media pertumbuhan pH Temperatur Cation consentration Atmosphere Inokulum Antibiotic disc 18
  • 19. Etest Etest strip berisi gradien konsentrasi antimikroba Prinsip : Standar inokulum bakteri diinokulasikan pada Muller Hinton Agar. Strip Etest diletakkan diatas permukaan agar, setelah inkubasi akan terbentuk zone inhibisi. MIC dibaca pada pertumbuhan yang menyilang strip Etest. 19
  • 21. 21
  • 22. Penutup Tes kepekaan antimikroba merupakan hal yang sangat penting untuk terapi dan menurunkan prevalensi resistensi kuman. 22
  • 24. 24
  • 25. 25
  • 26. Inoculum The density of the suspension is adjusted to approximately 108 CFU/ml by comparing its turbidity to a McFarland 0,5 BaSO4 standard. The standard prepared by : 0,5 ml 0,048 M BaCl2 99,5 ml 0,36 N H2SO4 26
  • 28. 28
  • 29. 29
  • 30. 30
  • 31. 31
  • 32. Two new chromogenic media in the Oxoid Brilliance™ Resistant Screening Agar range are now available. Brilliance ESBL Agar and Brilliance VRE Agar can be used as screening tests to rapidly identify patients colonised with problematic Extended Spectrum Beta-Lactamase (ESBL) producing organisms and vancomycin resistant enterococci (VRE), allowing appropriate infection control and treatment to commence sooner for the best possible patient outcome. E. coli (blue colonies) and the KESC group (green colonies) on ESBL Agar 32
  • 33. Brilliance VRE Agar is a chromogenic screening plate for the detection of VRE. Following direct inoculation from faecal sample, swab, isolate or suspension, the medium provides presumptive identification of Enterococcusfaecium and Enterococcusfaecaliswithin 24 hours. Differentiation of vancomycin resistant E. faecium from E. faecalis is achieved through the inclusion of two chromogens that are targeted by specific enzymes. The action of these enzymes on the chromogens results in a build-up of colour within the colony. The colour produced depends on which enzymes the organisms possess. Additional antibiotics are present in combination with vancomycin, to suppress the growth of competing flora including E. gallinarum and E. casseliflavus, both of which are intrinsically resistant to vancomycin. Rapidmicrobiology.com 33
  • 34. KPCs are class A carbapenemases that reside on transferable plasmids and are capable of inactivating carbapenems, such as imipenem and meropenem. Since carbapenems are often used to treat infections caused by extended-spectrum beta lactamase (ESBL)-producing Gram-negative bacteria, carbapenemase production in Enterobacteriaceae can significantly limit treatment options for life-threatening diseases. KPCs occur most commonly in Klebsiellapneumoniae but have been seen in other species of Enterobacteraciae as well.CLSI (Clinical Laboratory Standards Institute) recommends the MHT be performed before reporting carbapenem susceptibility results if a clinical isolate has an elevated but susceptible carbapenem MIC. Susceptibility results may be reported without performing the MHT if a clinical isolate is intermediate or resistant to carbapenems, but clinical laboratories may want to perform the MHT for infection control and epidemiological reasons. 34
  • 35. 35
  • 36. 36
  • 37. 37
  • 38. 38
  • 39. 39
  • 40. 40
  • 41. 41
  • 42. In the Stokes controlled sensitivity test, a control organism is inoculated on part of a plate and the test organism is plated on the remainder. Disks are placed at the interface and the zones of inhibition are compared. The use of a sensitive control shows that the antibiotic is active, so that if the test organism grows up to the disk it may safely be assumed that the test organism is resistant to that drug.  Stokes' sensitivity test The test bacterium in the diagram is susceptible to drug "x" but resistant to drug "y". The disk containing drug "y" contains active antibiotic as shown by the zone of inhibition it causes in the control bacterium http://.www.bmb.leed.ac.uk/mbiol...sts.html 42
  • 43. The VITEK® 2 compact is an automated bacterial identification and antibiotic susceptibility testing (ID/AST) system. Designed for small to midsize microbiology laboratories, the VITEK 2 compact offers an extensive ID and AST database to improve laboratory efficiency.      Using multi-spectrum colorimetric and transmittance optic systems, the VITEK 2 compact detects changes in organism growth under various media and antibiotic concentrations. The instrument’s advanced expert system interprets the antibiotic-resistance patterns, validates the results, and reports the resistance phenotype useful to patient treatment and infection control. The system offers rapid results, providing increased productivity and improved workflow. bioMerieux 43
  • 44. Antimicrobial Susceptibility Test (Broth Dilution) This test used to test all the ABC isolates. This picture shows the most accurate method of determining the antimicrobial susceptibility of GBS. This test is called the broth dilution antimicrobial susceptibility test. It is standardized by the the National Committee on Clinical Laboratory Standards (NCCLS). The picture above shows a microtiter plate with 96 wells. There are 8 rows of wells, labeled A through G. Each row of wells contains one antibiotic. In each row there are 12 wells. Each well contains a different concentration of the specific antibiotic, usually doubling dilutions. In this case, row A contains penicillin starting at the right at 16 ?g/ml and reducing to 0.008 well 12. Row B contains ampicillin starting in well 1 with 16 ?g/ml and reducing to 0.008 ?g/ml to well 12 in the same row. The other rows contain different antibiotics. All 96 wells are inoculated at the same time and the panel is incubated overnight (20-24h). The next day the wells are examined for growth. If there is growth in the well, the antibiotic did not inhibit the bacteria. If you take a close look in row A you will see growth (a small white button at the bottom of the well) only in well 12. In row B you see growth in both well 11 and 12. This means the minimum inhibitory concentration (MIC) of penicillin is 0.016 ?g/ml and the MIC for ampicillin is 0.032 ?g/ml. The MIC’s of these antimicrobials are considered susceptible for,GBS. Erythromycin is shown is row F. The concentration of erythromycin starts at 32 ?g/ml in well 1 and goes to 0.016 ?g/ml in well 12. You can see that there is growth in wells 12 to 4, meaning the MIC of erythromycin to this strain is 8 ?g/ml. This MIC is considered resistant for GBS. Since this is a standardized test results can be compared world-wide if the standard procedures are used. Consult the NCCLS manual for reporting interpretive standards (sensitive, intermediate, and resistance).NCCLS Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement: M100-12 (2002) M2-A7 and M7-A5. 44
  • 45. Testing of streptococcal isolates with erythromycin and clindamycin disks applied close together can often yield phenotypic information, although it is not always possible to differentiate between phenotypes using this method. See J. Clin. Microbiol 2001;39:1311-1315 for details of this method for phenotypic analysis of S. pneumoniae. The figures below are taken from that paper, with some major modifications made to simplify this discussion; see the paper for the real and more complicated story.                         45
  • 46.
  • 47. 47
  • 48. 48
  • 49. 49
  • 50. 50
  • 51. 51
  • 52. 52
  • 53. 53
  • 54. 54